Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy

Next Previous
X
Search
Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ertugliflozin (Primary) ; Glimepiride; Insulin; Metformin
  • Indications Obesity; Overweight; Type 2 diabetes mellitus
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms VERTIS; VERTIS MET
  • Sponsors Merck Sharp & Dohme; Merck Sharp & Dohme Corp.

    • Most Recent Events

    • 03 Feb 2023 Results of pooled post hoc analysis from two studies(n=445; NCT02033889 and NCT02630706) assessing the efficacy and safety of ertugliflozin in participants from Asia with T2D and baseline BMI 24 kg/m(2), with inadequate glycemic control on metformin published in the Diabetes Therapy
    • 31 Mar 2020 Results of post hoc analysis of two randomised controlled trials (NCT01999218 [VERTIS SU] and NCT02033889 [VERTIS MET) published in the Diabetologia
    • 26 Mar 2020 Results (n=1544) of post hoc and pooled analysis from NCT01958671, NCT02033889, and NCT02036515 assessing Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus, published in the Obesity (Silver Spring, Md.)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top